Effect of concurrent use of anti-retroviral therapy and levonorgestrel sub-dermal implant for contraception on CD4 counts: A prospective cohort study in Kenya

Journal of the International AIDS Society

Volumn 16, Issue , 2013, Pages

  Hubacher, David ^a   Liku, Jennifer ^a   Kiarie, James ^b,c   Rakwar, Joel ^b   Muiruri, Peter ^c   Omwenga, Jackline ^b   Chen, Pai Lien ^a  

^a FAMILY HEALTH INTERNATIONAL   (United States)

^b UNIVERSITY OF NAIROBI   (Kenya)

^c KENYATTA NATIONAL HOSPITAL   (Kenya)

Author keywords

ART; CD4; Contraception; Disease progression; Effectiveness; Interactions; Levonorgestrel sub dermal implant; Prospective cohort study

Indexed keywords

GESTAGEN; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; LEVONORGESTREL; STAVUDINE; TENOFOVIR DISOPROXIL; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CONTRACEPTIVE AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DERMAL IMPLANT; DEVICE REMOVAL; DRUG EFFICACY; FEMALE; FOLLOW UP; HERPES ZOSTER; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMPLANT; KENYA; MAJOR CLINICAL STUDY; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; PROGESTERONE RELEASE; PROSPECTIVE STUDY; THRUSH; YOUNG ADULT; ADOLESCENT; ART; CONTRACEPTION; DISEASE COURSE; EFFICACY; IMMUNOLOGY; INTERACTIONS; LEVONORGESTREL SUB-DERMAL IMPLANT; PREGNANCY; PROSPECTIVE COHORT STUDY;

ART; CD4; CONTRACEPTION; DISEASE PROGRESSION; EFFECTIVENESS; INTERACTIONS; LEVONORGESTREL SUB-DERMAL IMPLANT; PROSPECTIVE COHORT STUDY;

ADOLESCENT; ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; CONTRACEPTIVE AGENTS; FEMALE; HIV INFECTIONS; HUMANS; KENYA; LEVONORGESTREL; PREGNANCY; PROSPECTIVE STUDIES; YOUNG ADULT;

MLCS; MLOWN;

EID: 84879161297     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.16.1.18448     Document Type: Article

References (19)

1. United Nations. World Contraceptive Use 2011. 2011 [cited 2012 March 8]. Available from: http://www.un.org/esa/population/publications/contraceptive2011/ contraceptive2011.htm.
2. WHO. Global HIV AIDS Response Epidemic update and health sector progress toward universal access Progress Report 2011. 2012 [cited 2012 March 9]. Available from: http://whqlibdoc.who.int/publications/2011/9789241502986-eng. pdf.
3. Baeten JM, Lavreys L, Sagar M, Kreiss JK, Richardson BA, Chohan B, et al. Effect of contraceptive methods on natural history of HIV: studies from the Mombasa cohort. J Acquir Immune Defic Syndr. 2005;38(Suppl 1):S18-21.
4. Lavreys L, Baeten JM, Chohan V, McClelland RS, Hassan WM, Richardson BA, et al. Higher set point plasma viral load and more-severe acute HIV type 1 (HIV-1) illness predict mortality among high-risk HIV-1-infected African women. Clin Infect Dis. 2006;42:1333-9.
5. Stringer EM, Kaseba C, Levy J, Sinkala M, Goldenberg RL, Chi BH, et al. A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol. 2007;197:144.e1-8.
6. Curtis KM, Nanda K, Kapp N. Safety of hormonal and intrauterine methods of contraception for women with HIV/AIDS: a systematic review. AIDS. 2009;23(Suppl 1):S55-67.
7. Stringer E, Antonsen E. Hormonal contraception and HIV disease progression. Clin Infect Dis. 2008;47:945-51.
8. Phillips SJ, Curtis KM, Polis CB. Effect of hormonal contraceptive methods on HIV disease progression: a Systematic Review. AIDS. 2012, Nov 6. [Epub ahead of print].
9. El-Ibiary SY, Cocohoba JM. Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptives. Eur J Contracept Reprod Health Care. 2008;13:123-32.
10. Morrison CS, Richardson BA, Mmiro F, Chipato T, Celentano DD, Luoto J, et al. Hormonal contraception and the risk of HIV acquisition. AIDS. 2007;21:85-95.
11. Nanda K, Amaral E, Hays M, Viscola MA, Mehta N, Bahamondes L. Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy. Fertil Steril. 2008;90:965-71.
12. Heikinheimo O, Lehtovirta P, Suni J, Paavonen J. The levonorgestrel- releasing intrauterine system (LNG-IUS) in HIV-infected women - effects on bleeding patterns, ovarian function and genital shedding of HIV. Hum Reprod. 2006;21:2857-61.
13. McCarty EJ, Keane H, Quinn K, Quah S. Implanon(R) failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies. Int J STD AIDS. 2011;22:413-4.
14. Leticee N, Viard JP, Yamgnane A, Karmochkine M, Benachi A. Contraceptive failure of etonogestrel implant in patients treated with antiretrovirals including efavirenz. Contraception. 2012;85:425-427.
15. WHO. Hormonal contraception and HIV. Technical statement. 2012 [cited 2012 March 30]. Available from: http://whqlibdoc.who.int/hq/2012/WHO-RHR-12.08- eng.pdf.
16. WHO. Family planning handbook: a global handbook for providers. 2011 [cited 2012 January 30]. Available from: http://www.globalhandbook.org/.
17. Hubacher D, Dorflinger L. Avoiding controversy in international provision of subdermal contraceptive implants. Contraception. 2012;85:432-3.
18. UNAIDS. UNAIDS World AIDS Day Report 2011. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS; 2012.
19. UNAIDS. Global plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive. 2011 [cited 2012 March 30]. Available from: http://whqlibdoc.who.int/hq/2012/WHO-RHR-12.08-eng.pdf.